Pediatric oncologists unfamiliar with long-term follow-ups for childhood cancer survivors
Using survey responses from 655 pediatric oncologists in the US, researchers from the University of Chicago, Dana-Farber Cancer Institute, and Children's Hospital Boston concluded that many pediatric oncologists in the US are not familiar with long-term follow-up (LTFU) surveillance guidelines for childhood cancer survivors.
Researchers created a 'clinical vignette' of a 29 year old woman who, when she was 16, had been treated with mantle radiation for Hodgkin's lymphoma and asked the oncologists to make recommendations according to current long-term follow-up (LTFU) guidelines.
- 34% of respondents did not appropriately recommend yearly breast cancer surveillance;
- 43% of respondents did not appropriately recommend cardiac surveillance;
- 24% of respondents did not appropriately recommend yearly thyroid surveillance.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
